Annals of Surgical Oncology

, Volume 21, Issue 6, pp 1825–1833 | Cite as

Surgical Resection Versus Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis

  • Po-Hong Liu
  • Yun-Hsuan Lee
  • Cheng-Yuan Hsia
  • Chia-Yang Hsu
  • Yi-Hsiang Huang
  • Yi-You Chiou
  • Han-Chieh Lin
  • Teh-Ia Huo
Hepatobiliary Tumors

Abstract

Background

The long-term survival in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) who received surgical resection (SR) or transarterial chemoembolization (TACE) remains unclear. We compared the efficacy of SR and TACE by using a propensity score analysis.

Methods

A total of 247 and 181 HCC patients with PVTT undergoing SR and TACE, respectively, were evaluated. One hundred eight pairs of matched patients were selected from each treatment arm by using a propensity score analysis.

Results

Of all patients, the estimated 1-, 3-, and 5-year survival rates of patients receiving SR and TACE were 85 versus 60 %, 68 versus 42 %, and 61 versus 33 %, respectively (p < 0.001). Patients selected for SR were significantly younger and had better liver functional reserve, performance status, and smaller tumor burden. In the propensity model, the survival benefit of SR remained significant. The estimated 1-, 3-, and 5-year survival rates of patients receiving SR and TACE were 84 versus 71 %, 69 versus 50 %, and 59 versus 35 %, respectively (p = 0.004). The two groups of patients in the propensity score analysis were similar in baseline characteristics. In the Cox proportional hazards model, patients receiving TACE had a 2.044-fold increased risk of mortality compared with patients receiving SR (95 % confidence interval: 1.284–3.252, p = 0.003).

Conclusions

For either unselected patients or patients in the propensity model, SR provides significantly better long-term survival than TACE. SR should be considered as a priority treatment in this subgroup of HCC patients.

Keywords

Propensity Score Tace Barcelona Clinic Liver Cancer Propensity Score Analysis Meld Score 

Notes

Acknowledgment

This study was supported by Grants from the Center of Excellence for Cancer Research at Taipei Veterans General Hospital (DOH102-TD-C-111-007), Taiwan, from Taipei Veterans General Hospital (V102C-012), Taipei, Taiwan, and from the Ministry of Education, Aim for the Top University Plan (101AC-D101), Taiwan.

Disclosure

There are no conflicts of interest in all authors.

References

  1. 1.
    GLOBOCAN 2008 v2.0. Cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. 2010. http://globocan.iacr.fr. Accessed on 1 May 2013.
  2. 2.
    El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.PubMedCrossRefGoogle Scholar
  3. 3.
    Hsu CY, Hsia CY, Huang YH, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer. 2010;116:3006–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Bruix J, Sherman M; American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol. 2012;56(Suppl 1):S75–87.PubMedCrossRefGoogle Scholar
  6. 6.
    Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Lau WY, Sangro B, Chen PJ, et al. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84:311–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18:413–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–74.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. Surg Today. 2013.Google Scholar
  11. 11.
    European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.Google Scholar
  12. 12.
    Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis. 1988;8:12–25.PubMedCrossRefGoogle Scholar
  13. 13.
    Hsu CY, Lee YH, Hsia CY, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology. 2013;57:112-9.PubMedCrossRefGoogle Scholar
  14. 14.
    Kikuchi LO, Paranagua-Vezozzo DC, Chagas AL, et al. Nodules less than 20 mm and vascular invasion are predictors of survival in small hepatocellular carcinoma. J Clin Gastroenterol. 2009;43:191–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Hsu CY, Huang YH, Hsia CY, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol. 2010;53:108–17.PubMedCrossRefGoogle Scholar
  17. 17.
    Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44:723–31.PubMedCrossRefGoogle Scholar
  18. 18.
    Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:S115–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Hsu CY, Hsia CY, Huang YH, et al. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol. 2012;19:842-9.PubMedCrossRefGoogle Scholar
  20. 20.
    Lee YH, Hsu CY, Huang YH, et al. Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Gastroenterol Hepatol. 2012;27:1581–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Pearl J. Understanding propensity scores. Causality: models, reasoning and inference. 2nd edn. Cambridge: Cambridge University Press; 2009.CrossRefGoogle Scholar
  22. 22.
    Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Shi J, Lai EC, Li N, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol. 2010;17:2073–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol. 2006;12:7561–7.PubMedGoogle Scholar
  25. 25.
    Jamieson NV. Changing perspectives in portal vein thrombosis and liver transplantation. Transplantation. 2000;69:1772–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS, Lau WY. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2012;118:4725–36.PubMedCrossRefGoogle Scholar
  27. 27.
    Le Treut YP, Hardwigsen J, Ananian P, et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg. 2006;10:855–62.PubMedCrossRefGoogle Scholar
  28. 28.
    Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery. 2005;137:403–10.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Po-Hong Liu
    • 1
    • 4
  • Yun-Hsuan Lee
    • 1
    • 4
  • Cheng-Yuan Hsia
    • 1
    • 5
  • Chia-Yang Hsu
    • 1
    • 4
    • 7
  • Yi-Hsiang Huang
    • 2
    • 4
  • Yi-You Chiou
    • 1
    • 6
  • Han-Chieh Lin
    • 1
    • 4
  • Teh-Ia Huo
    • 1
    • 3
    • 4
    • 8
  1. 1.Faculty of MedicineNational Yang-Ming University School of MedicineTaipeiTaiwan
  2. 2.Institute of Clinical MedicineNational Yang-Ming University School of MedicineTaipeiTaiwan
  3. 3.Institute of PharmacologyNational Yang-Ming University School of MedicineTaipeiTaiwan
  4. 4.Department of MedicineTaipei Veterans General HospitalTaipeiTaiwan
  5. 5.Department of SurgeryTaipei Veterans General HospitalTaipeiTaiwan
  6. 6.Department of RadiologyTaipei Veterans General HospitalTaipeiTaiwan
  7. 7.Department of BiostatisticsUCLALos AngelesUSA
  8. 8.Division of Gastroenterology, Department of MedicineTaipei Veterans General HospitalTaipeiTaiwan

Personalised recommendations